antibodies news from FierceBiotech
News
ALSO NOTED: GSK releases new Cervarix data; FDA mulls DTC ads; and much more...
> GlaxoSmithKline has released new Cervarix data that demonstrates the vaccine's ability to generate a high and sustained level of antibodies to neutralize the two most prevalent strains of Read more...
Talecris' antibody drug gets priority review
The FDA has granted priority review to Talecris' drug Gamunex, meaning the FDA will review its application in six months rather than the standard 10. Gamunex is an IGIV therapy that contains Read more...
ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
Novartis reports strong meningitis vaccine response
In a head-to-head trial, researchers for Novartis say that the experimental meningitis vaccine Menveo produced a more potent immune response than the standard therapy in use. And other data has Read more...
EUSA Pharma spins off assets as it narrows focus
The transatlantic EUSA Pharma has spun off its monoclonal antibody research operation along with a development program for leukemia as it narrows its focus to late-stage drug development and Read more...
Breakthrough reported in flu vaccine research
A Japanese chemical company saw its stock shoot up 20 percent this morning, the maximum allowed on the Japanese market, after researchers for NOF and Japan's National Institute of Infectious Diseases Read more...
Morphotek licenses anti-cancer antibody
Morphotek has inked a deal with Human Monoclonals International to get rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. The company hopes to develop a lead Read more...
Officials toss Genentech antibody patent
Genentech says the U.S. Patent Office has rejected a patent covering the way it uses recombinant DNA technology to make antibodies. The biotech giant says it uses the 415 patent in making a number of Read more...
FDA approves Wyeth's hemophilia therapy
Wyeth has won FDA approval Xyntha, a treatment for patients with hemophilia A, a rare blood-clotting disorder in which sufferers lack a key protein (Factor VIII) that prevents excessive bleeding. Read more...
Genmab buys antibody plant in $240M deal
PDL BioPharma has inked a deal to sell its U.S. antibody manufacturing plant to Denmark's Genmab for $240 million. The deal--which will enable Genmab to transition three Read more...
Get more antibodies coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight